Article info
PDFClinical ethics
To test or not to test: genetic cancer predisposition testing in paediatric patients with cancer
- Correspondence to Dr Dennis John Kuo, Pediatric Hematology–Oncology, University of California San Diego School of Medicine, La Jolla CA 92093, USA; dekuo{at}ucsd.edu
Citation
To test or not to test: genetic cancer predisposition testing in paediatric patients with cancer
Publication history
- Received July 1, 2020
- Revised November 7, 2020
- Accepted November 16, 2020
- First published December 10, 2020.
Online issue publication
January 07, 2022
Article Versions
- Previous version (7 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes
- Osteonecrosis in patients with acute lymphoblastic leukaemia: a national questionnaire study
- Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia
- CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
- Health care utilisation following childhood acute lymphoblastic leukaemia: a population-based matched cohort study
- Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature
- TP53 c.455C>T p.(Pro152Leu) pathogenic variant is a lower risk allele with attenuated risks of breast cancer and sarcoma
- Multiple primary tumours: challenges and approaches, a review
- UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
- Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort